



NDA 50-641/S-008

Watson Laboratories, Inc.
Attention: Dorothy A. Frank, M.S., R.A.C.
Director, Regulatory Affairs
417 Wakara Way
Salt Lake City, UT 84108

Dear Ms. Frank:

Please refer to your supplemental new drug application dated July 18, 1994, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Monodox ® (doxycycline monohydrate), Capsules. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submission dated November 29, 1999. This submission constituted a complete response to our January 7, 1997 action letter.

This supplemental new drug application provides for revisions to the **Microbiology** subsection of the **CLINICAL PHARMACOLOGY** section of the package insert (PI).

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must include the enclosed revised labeling.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-641/S-008." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Judit Milstein, Regulatory Project Manager, at (301) 827-2207.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure: Revised labeling for the **CLINICAL PHARMACOLOGY**, *Microbiology* section of the PI

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth

3/21/02 02:46:50 PM